Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab + DCF in Induction for Locally Advanced SCCHN
NCT02997332Phase 1Terminated
- Sponsor
- Gustave Roussy
- Start
- Mar 2017
- Primary completion
- Mar 2020
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of durvalumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Gustave Roussy. Primary endpoints: Recommended Phase 2 dose at 10 weeks and Number of Dose Limiting Toxicity at 6 weeks. Started Mar 2017; status: terminated.
02
Drugs
durvalumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT02997332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02997332.